Medicines for Malaria Venture (MMV) is a not-for-profit public-private partnership that was established as a foundation in Switzerland in 1999.
Its main mission is to reduce malaria in disease-endemic countries by developing and facilitating the delivery of antimalarial drugs.
[1] MMV has a board of directors in North America, an Expert Scientific Advisory Committee which helps to identify projects, an Access & Product Management Advisory Committee and a Global Safety Board which reviews projects.
[2] MMV's project portfolio states that their goals are: MMV started the Open Source Malaria project,[3] which encourages people to share procedures and results of open source research.
[4] The Open Source Malaria, with researchers at the University of Sydney, supervised high school students at Sydney Grammar School who adapted a synthesis of Daraprim (pyrimethamine) using a less hazardous method.